JPM26: BMS’s Early-Stage Bets Are Happening Now, Amid Pharma’s Late-Stage Frenzy

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.